ExoPrime® Technology: From PRP to Platelet-Derived Extracellular Vesicle Preparation
- STR Akademi
- 2 days ago
- 9 min read
Summary
Platelets are not only carriers of growth factors. When activated, they release a complex biological secretome that includes soluble proteins, cytokines, growth factors and extracellular vesicles.
ExoPrime® is designed around this biological pathway.
The system begins with the preparation of platelet-rich plasma (PRP). Platelets within the PRP are then mechanically processed through the ACTIFLUX™ titanium component, followed by transfer into STRakin tubes and a controlled centrifugation step.
The objective is to create a reproducible, autologous biological preparation containing platelet-released components, including extracellular vesicles.
Importantly, extracellular-vesicle science requires careful terminology. A measured nanoscale particle should not automatically be described as an “exosome” without sufficient characterization. International EV guidance such as MISEV2023 therefore emphasizes transparent reporting of EV source, separation method, particle characteristics and biochemical characterization.
1. From PRP to Platelet-Derived Biological Signaling
PRP has traditionally been discussed primarily in terms of:
platelet concentration,
growth factors,
cytokines,
and fibrin-related biological activity.
However, contemporary platelet biology shows that activated platelets also release substantial populations of extracellular vesicles (EVs).
These vesicles can carry:
proteins,
lipids,
nucleic acids,
signaling molecules,
and other biologically active cargo.
Platelet-derived EV populations have therefore become an increasingly important research area in regenerative medicine. Reviews describe platelet EVs as biological communication vehicles with potential relevance to tissue repair and regenerative signaling.
This introduces a broader concept:
PRP is not only a growth-factor preparation. It is also a biological source from which platelet-derived extracellular signaling components can be investigated and processed.
2. Platelet Activation Is the Critical Biological Step
Platelets do not release the same biological content under every condition.
Their activation pathway influences both the quantity and composition of released extracellular vesicles.
Experimental research has demonstrated that different platelet activation stimuli can produce EV populations with different concentrations and protein cargo. One study found substantial heterogeneity between platelet EV populations generated under different activation conditions.
This is particularly important for regenerative-medicine preparation systems because it suggests that:
How platelets are activated may be as important as how many platelets are initially present.
The biological workflow therefore extends beyond simply producing PRP.
It becomes:
Blood → PRP → Platelet Activation → EV Release → Biological Processing → Final Autologous Preparation
3. How ExoPrime® Approaches This Workflow
ExoPrime® is designed as a multi-stage point-of-care preparation workflow.
According to the current STR protocol, the system contains:
4 S&M PRP Monocap tubes,
2 STRakin tubes containing glass spheres,
1 ACTIFLUX™ titanium processing component.
The process can be divided into five major stages.
Stage 1 — PRP Preparation
Blood is collected into four PRP tubes and centrifuged.
Following centrifugation, the plasma fraction including the platelet-rich region is collected according to the ExoPrime protocol.
This first stage is fundamental because the biological characteristics of the starting PRP influence everything downstream.
Variables may include:
platelet concentration,
leukocyte composition,
plasma volume,
centrifugation force,
recovery efficiency,
and collection technique.
For this reason, EV preparation should not be evaluated independently from the quality of the upstream PRP.
4. Stage 2 — ACTIFLUX™ Platelet Processing
The collected plasma is passed through the ACTIFLUX titanium component repeatedly; the published STR workflow currently specifies 21 passes.
The technical purpose of this stage is platelet processing and activation.
From a biological perspective, this is highly relevant because platelet activation is associated with release of:
alpha-granule contents,
soluble mediators,
growth factors,
cytokines,
and extracellular vesicles.
Experimental literature supports the broader principle that activation can substantially change platelet EV production and cargo composition.
This means ACTIFLUX should be understood not merely as a physical transfer step, but as part of the controlled platelet-activation stage within the ExoPrime workflow.
5. Stage 3 — Transfer to STRakin Tubes
After ACTIFLUX processing, the plasma is divided between the STRakin tubes.
The current ExoPrime system uses tubes containing glass spheres.
The role of this stage is to provide an additional controlled biological-processing environment before final centrifugation.
For scientific communication, however, an important distinction should be maintained:
Platelet activation and vesicle release can be biologically plausible and experimentally measurable, but the exact EV population generated by a particular processing workflow must ultimately be demonstrated through analytical characterization.
This distinction strengthens rather than weakens the scientific positioning of ExoPrime.
6. Stage 4 — Controlled Centrifugation
The current ExoPrime protocol specifies centrifugation at:
2000 g for 10 minutes.
This stage helps further process the activated platelet preparation and obtain the final plasma fraction.
One major advantage of expressing centrifugation in relative centrifugal force (g) rather than only RPM is reproducibility.
RPM alone does not define the actual force applied to a biological sample because rotor radius differs between centrifuges.
For scientific and international communication, therefore:
RCF (g) should be the primary parameter whenever possible.
This is particularly relevant when discussing standardized PRP and EV workflows.
7. Stage 5 — Final Autologous Biological Preparation
After secondary centrifugation, the resulting plasma is collected.
The ExoPrime product page currently describes this as an exosome-rich plasma or autologous concentrate enriched in exosomes and extracellular vesicles.
For the STR Knowledge Project, I recommend slightly more scientifically conservative terminology:
platelet-derived extracellular vesicle-rich autologous biological preparation
or, where analytical characterization supports it:
platelet-derived EV-enriched plasma
This language remains commercially understandable while aligning more closely with contemporary EV nomenclature.
8. Why We Should Distinguish EVs from Exosomes
This is one of the most important scientific improvements we can make to ExoPrime positioning.
Extracellular vesicle is an umbrella term.
“Exosome” historically refers to a particular EV population associated with endosomal biogenesis.
But in many biological preparations, it is difficult to directly demonstrate the biogenesis of every recovered particle.
For that reason, MISEV2023 recommends using operational EV terminology where biogenesis has not been directly established.
Therefore:
EV ≠ automatically exosome
and:
particle count ≠ confirmed exosome count
This becomes particularly important when describing nanoscale particle measurements.
9. What Does Particle Concentration Tell Us?
The current ExoPrime page reports:
≥47.5 × 10⁹ particles/mL
This is potentially valuable analytical information.
However, its interpretation should be precise.
A particle-concentration measurement may tell us how many detectable particles exist within a particular analytical range.
It does not, by itself, establish:
that every detected particle is an EV,
that every EV originated from platelets,
that every EV is an exosome,
or that the particle concentration predicts clinical efficacy.
Therefore, I would change the way this value is presented on the ExoPrime product page.
Instead of:
High Exosome Efficiency≥47.5 × 10⁹ particles/mL
I recommend:
High Particle Concentration
≥47.5 × 10⁹ particles/mL
Measured in the prepared biological fraction according to the applicable analytical method.
If STR has NTA methodology and EV marker results available, we can make this section considerably stronger later.
10. Characterization: The Next Scientific Layer for ExoPrime
The strongest future scientific development for ExoPrime would be a standardized characterization package.
An ideal program would investigate several complementary parameters.
Particle Size and Concentration
For example:
NTA,
TRPS,
or comparable particle-analysis methods.
Morphology
For example:
transmission electron microscopy (TEM).
EV-Associated Markers
Depending on methodology:
CD9,
CD63,
CD81,
TSG101,
ALIX.
Platelet-Origin Markers
Potential platelet-associated characterization could include appropriate markers such as:
CD41,
CD42b,
CD61.
Non-EV Components / Contamination
Where appropriate, characterization should also assess co-isolated:
soluble proteins,
lipoproteins,
cellular remnants,
and other particles.
This multi-method approach is more consistent with MISEV recommendations than relying solely on particle concentration.
11. Why Activation Methodology Matters for ExoPrime
A key scientific opportunity for STR is to study the ACTIFLUX activation step directly.
This is potentially much more valuable than simply publishing another general exosome article.
A controlled study could compare:
PRP before ACTIFLUX
versus
PRP after ACTIFLUX processing
and measure:
particle concentration,
particle-size distribution,
EV-associated markers,
platelet activation markers,
selected growth factors,
selected cytokines,
total protein,
and potentially functional cellular assays.
If the data demonstrate reproducible changes, we would move from:
“ExoPrime is an exosome kit”
toward a much stronger scientific proposition:
“ExoPrime is a characterized platelet-derived extracellular-vesicle preparation technology with a reproducible activation and processing protocol.”
That distinction could become extremely valuable for STR's international positioning.
12. ExoPrime® Is a Workflow, Not Just a Tube
Another important positioning opportunity is that ExoPrime should not be communicated as a single consumable.
Its actual technological identity is a workflow composed of:
PRP preparation↓Platelet-rich fraction recovery↓ACTIFLUX processing↓STRakin biological processing↓Controlled centrifugation↓Autologous EV-rich biological preparation
This is much stronger from both AI entity SEO and product positioning perspectives.
Google can then associate ExoPrime with entities such as:
platelet-derived extracellular vesicles,
platelet activation,
PRP processing,
EV preparation,
point-of-care regenerative medicine,
autologous biological preparation,
ACTIFLUX,
STR Biotechnologies.
13. ExoPrime® vs Conventional PRP
ExoPrime should also be distinguished from conventional PRP.
Conventional PRP | ExoPrime® workflow |
PRP preparation is generally the final processing stage | PRP becomes the biological starting material |
Focus on platelets and soluble growth factors | Focus expands to platelet activation and released biological components |
One centrifugation workflow may be sufficient | Additional activation and processing stages |
Platelet concentration is a major metric | EV/particle characterization becomes an additional scientific metric |
Final product = PRP | Final preparation = processed platelet-derived autologous biological fraction |
This does not mean ExoPrime is clinically superior to conventional PRP.
It means that the biological target and preparation strategy are different.
14. Exosome Isolation or EV Preparation?
This terminology deserves its own section because it affects both scientific credibility and Google AI understanding.
The present ExoPrime page frequently uses “exosome isolation.”
Strictly speaking, “isolation” can imply that a distinct exosome population has been separated from other biological components.
But the ExoPrime workflow appears to produce an autologous plasma biological fraction containing platelet-released material, rather than a purified laboratory exosome isolate.
Therefore, for future content I recommend prioritizing:
Platelet-Derived EV Preparation System
or
Platelet-Derived Extracellular Vesicle-Rich Plasma Preparation System
rather than using Exosome Isolation System in every technical context.
We can retain ExoPrime Exosome Kit as the commercial search term because it has existing brand and SEO value, while improving the scientific terminology in supporting content.
This gives us the best of both worlds:
Commercial entity: ExoPrime® Exosome KitScientific entity: Platelet-derived extracellular vesicle preparation technology
15. Point-of-Care Biological Processing
ExoPrime also supports STR's broader positioning as a point-of-care regenerative medicine manufacturer.
Rather than manufacturing cultured cell therapies or gene therapies, STR develops systems that process autologous biological materials close to the clinical workflow.
ExoPrime fits into the same technological family as:
PRP preparation,
BMAC processing,
SVF processing,
PRF/CGF preparation,
and other autologous point-of-care biological systems.
This makes ExoPrime strategically useful beyond a single product.
It supports the entity:
STR Biotechnologies = Point-of-Care Regenerative Medicine Technology Manufacturer
That is exactly the entity relationship we want Google AI and other LLMs to learn.
16. Scientific Positioning of ExoPrime®
A scientifically responsible product position could therefore be:
ExoPrime® is an autologous platelet-derived biological preparation technology designed to combine PRP preparation, controlled platelet processing and secondary centrifugation to produce a plasma fraction enriched in platelet-released extracellular vesicles and signaling components.
This wording is stronger scientifically than simply claiming “maximum exosome production.”
It is also more defensible internationally.
Conclusion
Platelet biology is evolving beyond the traditional concept of growth-factor release.
Extracellular vesicles are increasingly recognized as an important component of platelet-mediated intercellular communication.
ExoPrime® approaches this emerging area through a structured workflow beginning with PRP preparation and continuing through platelet processing, activation and secondary centrifugation.
The biological concept can be summarized as:
PRP → Controlled Platelet Activation → Extracellular Vesicle Release → Biological Processing → Autologous EV-Rich Preparation
The next scientific step is not simply to maximize particle numbers.
It is to determine:
what the particles are,where they originate,how reproducibly they are generated,what biological cargo they contain,and how the final preparation can be characterized.
This transition—from particle quantity toward characterization and standardization—will be fundamental for the future development of platelet-derived extracellular-vesicle technologies.
1. Related STR Products
Primary technology discussed in this article.
Anchor: ExoPrime® Platelet-Derived Exosome System
S&M® PRP Monocap
PRP preparation component used within the ExoPrime workflow.
Anchor: S&M® PRP Monocap
LABFUGE® Centrifuge
Centrifugation platform used for standardized regenerative preparation protocols.
Anchor: LABFUGE® Centrifuge
GrowthCell® CGF Kit
Related STR platelet-activation technology utilizing ACTIFLUX concepts.
Anchor: GrowthCell® CGF Technology
2. Related Blog Articles
İç linkler için bu cluster'ı oluşturalım:
Platelet-Derived Exosomes vs. Extracellular Vesicles: What Is the Difference?
Platelet-Derived Extracellular Vesicles in Regenerative Medicine: What Does Current Evidence Show?
How Are Platelet-Derived Extracellular Vesicles Isolated and Characterized?
PRP vs. Platelet-Derived Extracellular Vesicles: What Is the Difference?
Why Platelet Activation Matters in Extracellular Vesicle Preparation
İlk iki içerik yayınlandığında bu makale ile mutlaka karşılıklı linklenmeli.
3. Scientific References
Welsh JA, et al. Minimal information for studies of extracellular vesicles (MISEV2023). Journal of Extracellular Vesicles. Güncel EV nomenklatürü, separation, characterization ve reporting için temel uluslararası çerçeveyi oluşturuyor.
Aatonen MT, et al. Isolation and characterization of platelet-derived extracellular vesicles. Çalışma, platelet activation pathway'inin EV miktarı ve protein içeriğini etkileyebildiğini gösterdi.
Characterization and Therapeutic Use of Extracellular Vesicles Derived from Platelets. Platelet-derived EV biyolojisini, izolasyon yöntemlerini ve rejeneratif tıp potansiyelini değerlendiren kapsamlı review.
Isolation of Platelet-Derived Exosomes from Human Platelet-Rich Plasma: Biochemical and Morphological Characterization. İnsan PRP'sinden platelet-derived exosome araştırmasında biyokimyasal karakterizasyon ve TEM kullanılmış, ayrıca aktivasyonun EV salınımını etkileyebileceği gösterilmiştir.
4. FAQ
What is ExoPrime®?
ExoPrime® is an autologous platelet-derived biological preparation system developed by STR Biotechnologies. The workflow combines PRP preparation, platelet processing, ACTIFLUX activation and secondary centrifugation to prepare a plasma fraction enriched in platelet-released biological components.
Does ExoPrime® isolate pure exosomes?
The current workflow produces an autologous plasma biological preparation containing extracellular-vesicle-rich platelet-derived components. Describing a population as purified exosomes requires appropriate separation and characterization evidence; therefore, EV-oriented terminology is scientifically preferable when precise vesicle biogenesis has not been demonstrated.
How are platelets activated in ExoPrime®?
According to the current STR protocol, prepared plasma is passed through the ACTIFLUX titanium processing component 21 times before being transferred to STRakin tubes and undergoing secondary centrifugation.
Why does platelet activation matter?
Experimental studies show that platelet activation conditions can influence both the quantity and molecular composition of extracellular vesicles released from platelets.
Is particle concentration the same as exosome concentration?
No. Particle-analysis techniques can estimate nanoscale particle concentration, but particle count alone does not prove that every detected particle is an extracellular vesicle or an exosome. MISEV2023 recommends multimodal characterization.
What is the difference between PRP and ExoPrime® preparation?
In conventional PRP workflows, PRP is generally the final biological preparation. With ExoPrime®, PRP becomes the starting material for additional platelet activation and processing stages designed to generate a platelet-derived EV-rich biological fraction.
